Hofman J - Search Results

1

Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.

Novotná E, Büküm N, Hofman J, Flaxová M, Kouklíková E, Louvarová D, Wsól V. Novotná E, et al. Among authors: hofman j. Biochem Pharmacol. 2018 Oct;156:22-31. doi: 10.1016/j.bcp.2018.08.001. Epub 2018 Aug 3. Biochem Pharmacol. 2018. PMID: 30077642

2

Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.

Hofman J, Ahmadimoghaddam D, Hahnova L, Pavek P, Ceckova M, Staud F. Hofman J, et al. Pharmacol Res. 2012 Mar;65(3):312-9. doi: 10.1016/j.phrs.2011.11.017. Epub 2011 Dec 6. Pharmacol Res. 2012. PMID: 22173067

3

Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1).

Hofman J, Kučera R, Cihalova D, Klimes J, Ceckova M, Staud F. Hofman J, et al. PLoS One. 2013 Oct 8;8(10):e75520. doi: 10.1371/journal.pone.0075520. eCollection 2013. PLoS One. 2013. PMID: 24116053 Free PMC article.

4

Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro.

Cihalova D, Hofman J, Ceckova M, Staud F. Cihalova D, et al. Among authors: hofman j. PLoS One. 2013 Dec 23;8(12):e83467. doi: 10.1371/journal.pone.0083467. eCollection 2013. PLoS One. 2013. PMID: 24376706 Free PMC article.

5

Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors.

Skarydova L, Hofman J, Chlebek J, Havrankova J, Kosanova K, Skarka A, Hostalkova A, Plucha T, Cahlikova L, Wsol V. Skarydova L, et al. Among authors: hofman j. J Steroid Biochem Mol Biol. 2014 Sep;143:250-8. doi: 10.1016/j.jsbmb.2014.04.005. Epub 2014 Apr 24. J Steroid Biochem Mol Biol. 2014. PMID: 24769118

6

Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.

Hofman J, Malcekova B, Skarka A, Novotna E, Wsol V. Hofman J, et al. Toxicol Appl Pharmacol. 2014 Aug 1;278(3):238-48. doi: 10.1016/j.taap.2014.04.027. Epub 2014 May 14. Toxicol Appl Pharmacol. 2014. PMID: 24832494

7

Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases.

Hofman J, Skarka A, Havrankova J, Wsol V. Hofman J, et al. Biochem Pharmacol. 2015 Aug 1;96(3):168-78. doi: 10.1016/j.bcp.2015.05.005. Epub 2015 May 15. Biochem Pharmacol. 2015. PMID: 25986883

8

Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).

Hofman J, Kučera R, Neumanova Z, Klimes J, Ceckova M, Staud F. Hofman J, et al. Xenobiotica. 2016;46(5):416-23. doi: 10.3109/00498254.2015.1086039. Epub 2015 Sep 12. Xenobiotica. 2016. PMID: 26364927

9

Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.

Zemanova L, Hofman J, Novotna E, Musilek K, Lundova T, Havrankova J, Hostalkova A, Chlebek J, Cahlikova L, Wsol V. Zemanova L, et al. Among authors: hofman j. J Nat Prod. 2015 Nov 25;78(11):2666-74. doi: 10.1021/acs.jnatprod.5b00616. Epub 2015 Nov 3. J Nat Prod. 2015. PMID: 26529431

10

Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.

Hintzpeter J, Seliger JM, Hofman J, Martin HJ, Wsol V, Maser E. Hintzpeter J, et al. Among authors: hofman j. Toxicol Appl Pharmacol. 2016 Feb 15;293:21-9. doi: 10.1016/j.taap.2016.01.003. Epub 2016 Jan 7. Toxicol Appl Pharmacol. 2016. PMID: 26773812

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters